In a 26-week dermal oncogenicity study, topical capsaicin (the prototypical TRPV1 agonist) did not increase papilloma formation in the mouse skin treated by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA) [81]. Here, TRPV1 is linked to papilloma.